Advertisement

COPD is not only one of the several VTE risk factors

  • Laurent BERTOLETTI
    Correspondence
    Corresponding author at: CHU de St-Etienne, Service de Médecine Vasculaire et Thérapeutique, Saint-Etienne F-42055, France.
    Affiliations
    Centre Hospitalo-Universitaire de Saint-Etienne, Service de Médecine Vasculaire et Thérapeutique; INSERM, CIC 1408, CHU de St-Etienne; INSERM, UMR 1059, Université Jean Monnet; FCRIN INNOVTE, France
    Search for articles by this author
  • Francis COUTURAUD
    Affiliations
    Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, Département de Médecine Interne et Pneumologie, CIC INSERM 1412, Brest, FCRIN INNOVTE EA 3878, France
    Search for articles by this author
Published:December 24, 2020DOI:https://doi.org/10.1016/j.ejim.2020.12.013
      Chronic obstructive pulmonary disease (COPD) is a frequent and severe chronic respiratory disease [

      Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf.

      ]. It is ranked in the 5th main causes of death worldwide [

      Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf.

      ]. Patients with COPD suffer from persistent dyspnea, with periods of acute worsening, called exacerbation. One third of COPD patients need to be hospitalized because of severe exacerbation [

      Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf.

      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 report. 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf.

        • Torbicki A.
        • Perrier A.
        • Konstantinides S.
        • Agnelli G.
        • Galiè N.
        • Pruszczyk P.
        • Bengel F.
        • Brady A.J.B.
        • Ferreira D.
        • Janssens U.
        • Klepetko W.
        • Mayer E.
        • Remy-Jardin M.
        • Bassand J.-P.
        • Vahanian A.
        • Camm J.
        • De Caterina R.
        • Dean V.
        • Dickstein K.
        • Filippatos G.
        • Funck-Brentano C.
        • Hellemans I.
        • Kristensen S.D.
        • McGregor K.
        • Sechtem U.
        • Silber S.
        • Tendera M.
        • Widimsky P.
        • Zamorano J.-L.L.
        • Andreotti F.
        • et al.
        Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).
        Eur Heart J. 2008; 29: 2276-2315
        • Harenberg J.
        • Verhamme P.
        The dangerous liaisons between chronic obstructive pulmonary disease and venous thromboembolism.
        Thromb Haemost. 2020; 120: 363-365https://doi.org/10.1055/s-0039-1701012
        • Le Mao R.
        • Tromeur C.
        • Bazire A.
        • Gouillou M.
        • Guegan M.
        • Lacut K.
        • Delluc A.
        • Mottier D.
        • Leroyer C.
        • Couturaud F.
        Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study.
        Eur Respir J. 2017; 50 (10.1183/13993003.00094-2017)1700094
        • Børvik T.
        • Brækkan S.K.
        • Enga K.
        • Schirmer H.
        • Brodin E.E.
        • Melbye H.
        • Hansen J.-B.
        COPD and risk of venous thromboembolism and mortality in a general population.
        Eur Respir J. 2016; 47: 473-481
        • Bertoletti L.
        • Quenet S.
        • Mismetti P.
        • Hernández L.
        • Martín-Villasclaras J.J.
        • Tolosa C.
        • Valdés M.
        • Barrón M.
        • Todolí J.A.
        • Monreal M.
        • Investigators R.
        Clinical presentation and outcome of venous thromboembolism in COPD.
        Eur Respir J. 2012; 39: 862-868https://doi.org/10.1183/09031936.00058811
        • Majoor C.J.
        • Kamphuisen P.W.
        • Zwinderman A.H.
        • Ten Brinke A.
        • Amelink M.
        • Rijssenbeek-Nouwens L.
        • et al.
        Risk of deep-vein thrombosis and pulmonary embolism in asthma.
        Eur Respir J. 2013; 42: 655-661https://doi.org/10.1183/09031936.00150312
        • Sprunger D.B.
        • Olson A.L.
        • Huie T.J.
        • Fernandez-Perez E.R.
        • Fischer A.
        • Solomon J.J.
        • Brown K.K.
        • Swigris JJ.
        Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease.
        Eur Respir J. 2012; 39: 125-132
        • Bertoletti L.
        • Couturaud F.
        • Montani D.
        • Parent F.
        • Sanchez O.
        Venous thromboembolism and COVID-19.
        Respir Med Res. 2020; 78100759
        • Bertoletti L.
        The paradoxical association between pulmonary embolism and COPD.
        Eur Respir J. 2017; 501700959
        • Konstantinides S.V.
        • Meyer G.
        • Becattini C.
        • Bueno H.
        • Geersing G.-J.
        • Harjola V.-P.
        • Huisman M.V.
        • Humbert M.
        • Jennings C.S.
        • Jiménez D.
        • Kucher N.
        • Lang I.M.
        • Lankeit M.
        • Lorusso R.
        • Mazzolai L.
        • Meneveau N.
        • Ní Áinle F.
        • Prandoni P.
        • Pruszczyk P.
        • Righini M.
        • Torbicki A.
        • Van Belle E.
        • Zamorano J.L.
        • Galié N.
        • Gibbs J.S.R.
        • Aboyans V.
        • Ageno W.
        • Agewall S.
        • Almeida A.G.
        • Andreotti F.
        • et al.
        ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).
        Eur Heart J. 2019; 41 (2020): 543-603
        • de-Miguel-Diez J.
        • Albaladejo-Vicente R.
        • Jiménez-García R.
        • Hernandez-Barrera V.
        • Villanueva-Orbaiz R.
        • Carabantes-Alarcon D.
        • Jimenez D.
        • Monreal M.
        • López-de-Andrés A.
        The effect of COPD on the incidence and mortality of hospitalized patients with pulmonary embolism: a nationwide population-based study (2016-2018).
        Eur J Intern Med. 2020; https://doi.org/10.1016/j.ejim.2020.11.009
        • Jiménez D.
        • Agustí A.
        • Monreal M.
        • Otero R.
        • Huisman M.V.
        • Lobo J.L.
        • Quezada A.
        • Jara-Palomares L.
        • Hernando A.
        • Tabernero E.
        • Marcos P.
        • Ruiz-Artacho P.
        • Ballaz A.
        • Bertoletti L.
        • Couturaud F.
        • Yusen R.
        • Jimenez D.
        • Agustí A.
        • Bertoletti L.
        • Couturaud F.
        • Huisman M V.
        • Jimenez D.
        • Lobo J.L.
        • Monreal M.
        • Otero R.
        • Yusen R.D.
        • Muriel A.
        • Guerassimova I.
        • Morillo R.
        • Barrios D.
        • et al.
        The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease.
        Clin Cardiol. 2019; 42: 346-351
        • Lankeit M.
        • Held M.
        Incidence of venous thromboembolism in COPD: linking inflammation and thrombosis?.
        Eur Respir J. 2016; 47: 369-373

      Biography

      Dr. Bertoletti reports having received research grant support from Bayer and fees for board memberships or symposia from Actelion, Aspen, Bayer, Bristol-Myers Squibb/Pfizer, Léo-Pharma and MSD, and having received travel support from Aspen, Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Leo Pharma, MSD and Actelion.

      Biography

      Dr. Couturaud reports having received research grant support from Bristol-Myers Squibb/Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Leo Pharma, Intermune and Actelion.